Peter B. Gilbert

31.8k total citations · 7 hit papers
309 papers, 11.8k citations indexed

About

Peter B. Gilbert is a scholar working on Virology, Infectious Diseases and Statistics and Probability. According to data from OpenAlex, Peter B. Gilbert has authored 309 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Virology, 110 papers in Infectious Diseases and 94 papers in Statistics and Probability. Recurrent topics in Peter B. Gilbert's work include HIV Research and Treatment (145 papers), Advanced Causal Inference Techniques (58 papers) and Statistical Methods and Inference (56 papers). Peter B. Gilbert is often cited by papers focused on HIV Research and Treatment (145 papers), Advanced Causal Inference Techniques (58 papers) and Statistical Methods and Inference (56 papers). Peter B. Gilbert collaborates with scholars based in United States, South Africa and Germany. Peter B. Gilbert's co-authors include Lawrence Corey, Stanley A. Plotkin, Michael G. Hudgens, M. Juliana McElrath, Ying Huang, Steven G. Self, David C. Montefiori, Max Essex, John R. Mascola and Ann Duerr and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter B. Gilbert

289 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

2008 1.2k citations Susan Buchbinder, Devan V. Mehrotra et al. profile →
Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

2005 845 citations Leonidas Stamatatos, Marguerite Koutsoukos et al. profile →
Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

2006 569 citations Punnee Pitisuttithum, Peter B. Gilbert et al. profile →
Evidence for antibody as a protective correlate for COVID-19 vaccines

2021 475 citations Andrew Fioré-Gartland, Peter B. Gilbert et al. profile →
Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies

2009 446 citations Holly Janes, Peter B. Gilbert et al. profile →
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines

2022 109 citations Peter B. Gilbert, Richard A. Koup et al. profile →
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

2023 72 citations Peter B. Gilbert et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter B. Gilbert United States	51	5.9k	4.8k	3.2k	2.5k	2.5k	309	11.8k
Michael G. Hudgens United States	46	2.6k 0.4×	3.3k 0.7×	1.3k 0.4×	3.0k 1.2×	887 0.4×	293	8.7k
Richard A. Kaslow United States	61	7.5k 1.3×	6.6k 1.4×	6.0k 1.8×	6.8k 2.7×	1.5k 0.6×	221	19.8k
Steven G. Self United States	48	1.8k 0.3×	1.3k 0.3×	2.2k 0.7×	1.7k 0.7×	1.3k 0.5×	119	10.6k
Charles R. Rinaldo United States	66	9.4k 1.6×	8.0k 1.7×	6.6k 2.0×	7.2k 2.9×	1.8k 0.7×	347	19.6k
Joseph B. Margolick United States	64	12.9k 2.2×	10.2k 2.1×	4.8k 1.5×	4.1k 1.7×	2.3k 1.0×	257	19.7k
Martin Hirsch United States	72	13.0k 2.2×	13.6k 2.8×	3.8k 1.2×	7.2k 2.9×	1.9k 0.8×	274	24.1k
Alfred J. Saah United States	57	4.8k 0.8×	5.3k 1.1×	2.7k 0.8×	6.4k 2.6×	856 0.3×	165	13.6k
Glen A. Satten United States	45	4.7k 0.8×	7.1k 1.5×	487 0.2×	4.2k 1.7×	1.5k 0.6×	146	13.8k
Thomas C. Merigan United States	64	5.2k 0.9×	6.0k 1.3×	3.3k 1.0×	5.2k 2.1×	1.7k 0.7×	234	15.2k
Scott M. Hammer United States	52	10.2k 1.7×	12.3k 2.6×	908 0.3×	3.9k 1.5×	864 0.4×	129	16.0k

Countries citing papers authored by Peter B. Gilbert

Since Specialization

Citations

This map shows the geographic impact of Peter B. Gilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter B. Gilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter B. Gilbert more than expected).

Fields of papers citing papers by Peter B. Gilbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter B. Gilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter B. Gilbert. The network helps show where Peter B. Gilbert may publish in the future.

Co-authorship network of co-authors of Peter B. Gilbert

This figure shows the co-authorship network connecting the top 25 collaborators of Peter B. Gilbert. A scholar is included among the top collaborators of Peter B. Gilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter B. Gilbert. Peter B. Gilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Yanqing, et al.. (2025). Estimation and Hypothesis Testing of Strain‐Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID‐19 Vaccine Trial. Statistics in Medicine. 44(6). e10345–e10345.

Donnell, Deborah, David V. Glidden, Alex Luedtke, et al.. (2023). Study design approaches for future active-controlled HIV prevention trials. PubMed. 15(1). 20230002–20230002. 4 indexed citations

Wan, Alan T. K., Wei Zhao, Peter B. Gilbert, & Yong Zhou. (2022). A varying-coefficient partially linear transformation model for length-biased data with an application to HIV vaccine studies. The International Journal of Biostatistics. 19(1). 131–162.

Zhao, Lue Ping, Terry P. Lybrand, Peter B. Gilbert, et al.. (2021). Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses. 14(1). 9–9. 9 indexed citations

Lin, Dan-Yu, Donglin Zeng, & Peter B. Gilbert. (2021). Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases. 73(10). 1927–1939. 16 indexed citations

Lin, Dan-Yu, Yu Gu, Donglin Zeng, Holly Janes, & Peter B. Gilbert. (2021). Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases. 74(3). 544–552. 8 indexed citations

Andersen‐Nissen, Erica, Andrew Fioré-Gartland, Lamar Ballweber-Fleming, et al.. (2021). Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens. 17(3). e1009363–e1009363. 20 indexed citations

Gilbert, Peter B., Bryan S. Blette, Bryan E. Shepherd, & Michael G. Hudgens. (2020). Post-randomization Biomarker Effect Modification Analysis in an HIV Vaccine Clinical Trial. SHILAP Revista de lepidopterología. 8(1). 54–69. 4 indexed citations

Halloran, M. Elizabeth, Ira M. Longini, & Peter B. Gilbert. (2020). Designing a Study of Correlates of Risk for Ebola Vaccination. American Journal of Epidemiology. 189(8). 747–754. 2 indexed citations

10.

Zhao, Hui, Qiwei Wu, Peter B. Gilbert, Ying Qing Chen, & Jianguo Sun. (2020). A regularized estimation approach for case‐cohort periodic follow‐up studies with an application to HIV vaccine trials. Biometrical Journal. 62(5). 1176–1191. 7 indexed citations

11.

Lin, Dan-Yu, Donglin Zeng, Devan V. Mehrotra, Lawrence Corey, & Peter B. Gilbert. (2020). Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clinical Infectious Diseases. 73(8). 1540–1544. 11 indexed citations

12.

Duke, Elizabeth R., Brian D. Williamson, Bhavesh Borate, et al.. (2020). CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation. 131(1). 40 indexed citations

13.

Huang, Ying, et al.. (2019). Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials. The International Journal of Biostatistics. 16(1). 2 indexed citations

14.

Fourati, Slim, Susan Pereira Ribeiro, Aarthi Talla, et al.. (2019). Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. Nature Communications. 10(1). 863–863. 24 indexed citations

15.

Juraska, Michal, Craig A. Magaret, Jason Shao, et al.. (2018). Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences. 115(36). 48 indexed citations

16.

Wan, Alan T. K., et al.. (2017). Smoothed Rank Regression for the Accelerated Failure Time Competing Risks Model with Missing Cause of Failure. Statistica Sinica. 29(1). 23–46. 4 indexed citations

17.

Huang, Ying, Carlos A. DiazGranados, Holly Janes, et al.. (2016). Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Current Opinion in Virology. 17. 57–65. 7 indexed citations

18.

Fu, Rong & Peter B. Gilbert. (2016). Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling. Lifetime Data Analysis. 23(1). 136–159. 8 indexed citations

19.

Sachdev, Darpun, Hasan Ahmed, Yunda Huang, et al.. (2014). Sex Differences in Immune Variables in the RV144 Trial. AIDS Research and Human Retroviruses. 30(S1). A191–A191. 1 indexed citations

20.

Janes, Holly, Peter B. Gilbert, Susan Buchbinder, et al.. (2013). In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses. 29(11). 1513–1523. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact